Arun, Banu

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research

PARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers

Cited by 981

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesGene expression and cancer classification

Cited by 566

Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer

Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 521

Breast tumours maintain a reservoir of subclonal diversity during expansion

Minussi, D. C., Nicholson, M. D., Ye, H., Davis, A., Wang, K., Baker, T., Tarabichi, M., Sei, E., Du, H., Rabbani, M., et al. (2021) · Nature

Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomics

Cited by 256

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyEstrogen and related hormone effects

Cited by 161

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32, 295 women

EMBRACE, Rebbeck, T. R., HEBON, Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., Apostolou, P., Arnold, N., et al. (2016) · Breast Cancer Research

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 71

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 32

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

Nemati Shafaee, M., Goutsouliak, K., Lin, H., Bevers, T. B., Gutierrez-Barrera, A., Bondy, M., & Arun, B. (2022) · Breast Cancer Research and Treatment

BRCA gene mutations in cancerBreast Cancer Treatment Studies

Cited by 12